ProBioGen Partners with ModeX to Accelerate COVID-19 Antibody Development

ProBioGen, a contract development and manufacturing organization (CDMO) known for its solutions in cell engineering and bioprocessing excellence, has entered a collaboration with ModeX Therapeutics, an OPKO Health company.
 
ModeX has signed a Master Services Agreement with ProBioGen to accelerate the development and production of clinical material for their multi-specific COVID-19 antibody.
 
This strategic fee-for-service collaboration encompasses a full spectrum of services, including advanced cell line development, process optimization, and large-scale GMP production. ModeX will harness the power of ProBioGen’s DirectedLuck Transposase Technology, which enables the production of high-titer stable expression cell lines that are critical to the success of ModeX’s antibody program.
 
“ProBioGen is thrilled to work on ModeX´s fascinating complex COVID-19 antibodies,” said Dr. Volker Sandig, CSO at ProBioGen. “Our CHO.RiGHT platform together with the DirectedLuck transposase technology provides the robustness and flexibility to address specific needs of each molecule and create the very best cell line with accelerated time lines. The partnership represents a bold step toward industrial manufacturing of this important drug candidate.”
 
“We are excited to partner with ProBioGen to advance our COVID-19 antibody program,” added Dr. Peter Bernhardt, CMC Lead at ModeX. “This collaboration marks a pivotal moment in our mission to deliver transformative therapies for infectious diseases, and we are confident that our combined expertise will drive meaningful progress.”